- Home » News and EventsPage 12
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent and Stirling Ultracold Announce Partnership to Establish Energy-Efficient Cold Chain Capabilities for Biologics and Emerging Modalities
Apr 29, 2021
Catalent and Stirling Ultracold today announced a partnership whereby Stirling Ultracold becomes the preferred provider of ULT storage across Catalent’s multiple business units.
AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases
Apr 27, 2021
AavantiBio and Catalent today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).
Catalent Adds Cryogenic Capabilities at Philadelphia Clinical Supply Services Facility to Meet Growing Demand for Cell and Gene Therapy Development
Apr 15, 2021
Catalent today announced that it has made an investment to expand capabilities at its clinical supply services facility in Philadelphia to support sponsors developing cell and gene therapies.
Catalent Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity
Apr 13, 2021
Catalent has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs.
Catalent Experts to Discuss Supply Chain for New Modalities, and Direct-to-Patient Clinical Supply for Decentralized Trials at GCSG Events in April
Apr 7, 2021
Catalent announced that its clinical supply experts will be participating in upcoming Global Clinical Supplies Group (GCSG) events, discussing cell and gene therapy supply chains, direct-to-patient (DTP) services, and just-in-time delivery models.
Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio
Apr 6, 2021
Moderna and Catalent today announced the expansion of their strategic partnership to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine at Catalent’s facility in Bloomington, Indiana.
Catalent Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
Mar 22, 2021
Catalent has signed an agreement with Cybin Inc to apply Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for the delivery of Cybin’s novel deuterated tryptamine (CYB003), a potential therapy for treatment-resistant psychiatric disorders.
Catalent Expands Partnership with Johnson & Johnson to Significantly Increase Capacity for Sterile Manufacturing and Packaging of COVID-19 Vaccine in Italy
Mar 17, 2021
Catalent today announced Catalent Biologics will significantly increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at Catalent’s manufacturing facility in Anagni, Italy.
Catalent Responds to the Global Outbreak of COVID-19
Mar 17, 2021
As a development and manufacturing partner that supplies medicines, clinical trial materials, and health products to patients and consumers, we are taking action to minimize the impact of the COVID-19 pandemic.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.